For example, a patient with HER2-amplified breast cancer with cN1 and Ki67 >20 who received eight cycles of NAC with single targeted therapy and achieved bpCR had a total of 188 points, so the possibility of ypN0 after NAC for this patient was 88% (Figure 2B), and a patient with triple-negative breast cancer with cN1 and Ki67 >20 who received eight cycles of NAC and did not achieve bpCR had a total of 88 points, so the possibility of ypN0 after NAC for this patient was 40% (Figure 2C). This evidence concerns the gene MKI67 and triple-negative breast carcinoma.